Fieldpoint Private Securities LLC boosted its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 20.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,862 shares of the exchange traded fund’s stock after acquiring an additional 977 shares during the period. Fieldpoint Private Securities LLC’s holdings in SPDR S&P Biotech ETF were worth $507,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Quantitative Investment Management LLC grew its holdings in SPDR S&P Biotech ETF by 642.3% in the 2nd quarter. Quantitative Investment Management LLC now owns 1,451,998 shares of the exchange traded fund’s stock valued at $112,065,000 after buying an additional 1,256,398 shares in the last quarter. Wells Fargo & Company MN grew its holdings in SPDR S&P Biotech ETF by 2.7% in the 3rd quarter. Wells Fargo & Company MN now owns 1,449,462 shares of the exchange traded fund’s stock valued at $125,480,000 after buying an additional 38,545 shares in the last quarter. Assetmark Inc. grew its holdings in SPDR S&P Biotech ETF by 59.9% in the 3rd quarter. Assetmark Inc. now owns 1,239,051 shares of the exchange traded fund’s stock valued at $107,265,000 after buying an additional 464,246 shares in the last quarter. First Republic Investment Management Inc. grew its holdings in SPDR S&P Biotech ETF by 7.9% in the 3rd quarter. First Republic Investment Management Inc. now owns 408,745 shares of the exchange traded fund’s stock valued at $35,385,000 after buying an additional 29,852 shares in the last quarter. Finally, SG Americas Securities LLC grew its holdings in SPDR S&P Biotech ETF by 162.8% in the 3rd quarter. SG Americas Securities LLC now owns 303,622 shares of the exchange traded fund’s stock valued at $26,285,000 after buying an additional 188,106 shares in the last quarter.

Shares of SPDR S&P Biotech ETF (NYSEARCA XBI) traded down $1.44 during midday trading on Thursday, reaching $81.48. The company’s stock had a trading volume of 3,717,800 shares, compared to its average volume of 4,242,237. SPDR S&P Biotech ETF has a 52-week low of $58.66 and a 52-week high of $88.98.

COPYRIGHT VIOLATION WARNING: “SPDR S&P Biotech ETF (XBI) Shares Bought by Fieldpoint Private Securities LLC” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/14/spdr-sp-biotech-etf-xbi-shares-bought-by-fieldpoint-private-securities-llc.html.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.